CureVac to begin clinical trials for second-generation COVID-19 vaccine

German biotechnology company CureVac said on November 18 that clinical trials for its second-generation COVID-19 vaccine will begin in the next few months.

Highlights

• CureVac to begin clinical trials of its second-generation COVID-19 vaccine

GERMANY: PHARMACEUTICAL COMPANY CUREVAC RAISED 180 MILLION EURO IN ITS STOCK MARKET DEBUT

Highlights:

• On Friday, Germany’s biopharmaceutical company had generated 180 million euro in its debut in the stock market
• The company has sold its debut shares at a price of 13.3 million euro

CureVac which is the biopharmaceut...

GSK BUYS STAKE IN GERMAN CORONAVIRUS VACCINE MAKER

HIGHLIGHTS

• GlaxoSmithKline has bought 10% stake worth £ 130 million in CureVac.
• Stake of 10% is part of deal between two companies that could eventually be worth more than £ 800 million.

The British pharmaceutical company...